necitumumab

chemical compound

Uses your system voice; voice and rate in settings.

Q6985503Snapshot

≈ 1 min read

Names in other languages

  • Englishnecitumumab
  • EspañolNecitumumab
  • ItalianoNecitumumab
  • orନେସିଟୁମୁମାବ
  • Polskinecitumumab
  • РусскийНецитумумаб
  • العربيةنسيتوموماب
  • 中文耐昔妥珠单抗

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly. It binds to the epidermal growth factor receptor (EGFR). The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC). It was counterproductive in non-squamous non-small-cell lung carcinoma.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1253476994 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.